Mark Harries Selected Research

Drug Therapy (Chemotherapy)

1/2019	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
2/2014	Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial.
1/2013	Targeting brain metastases in patients with melanoma.
12/2007	Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience.
3/2003	Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
9/2002	Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease.
9/2002	Part I: chemotherapy for epithelial ovarian cancer-treatment at first diagnosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mark Harries Research Topics

Disease

20	Melanoma (Melanoma, Malignant) 02/2024 - 12/2007
11	Neoplasms (Cancer) 02/2023 - 04/2011
8	Breast Neoplasms (Breast Cancer) 04/2019 - 08/2005
4	Disease Progression 01/2022 - 04/2011
4	Neoplasm Metastasis (Metastasis) 04/2019 - 05/2014
2	Triple Negative Breast Neoplasms 11/2023 - 01/2018
2	Inflammation (Inflammations) 09/2022 - 04/2013
2	Brain Neoplasms (Brain Tumor) 10/2015 - 01/2013
2	Ovarian Epithelial Carcinoma 09/2002 - 09/2002
2	Ovarian Neoplasms (Ovarian Cancer) 09/2002 - 09/2002
1	COVID-19 01/2021
1	Cardiotoxicity 01/2019
1	Pathologic Complete Response 07/2014
1	Erectile Dysfunction 05/2014
1	Optic Neuritis (Retrobulbar Neuritis) 05/2014
1	Hypertension (High Blood Pressure) 05/2014
1	Drug-Related Side Effects and Adverse Reactions 05/2014
1	Carcinoma (Carcinomatosis) 09/2012
1	Renal Cell Carcinoma (Grawitz Tumor) 04/2011
1	Fatigue 04/2011
1	Lobular Carcinoma 08/2010
1	Metabolic Diseases (Metabolic Disease) 12/2007
1	Lymphoma (Lymphomas) 03/2003
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 03/2003
1	Hodgkin Disease (Hodgkin's Disease) 03/2003

Drug/Important Bio-Agent (IBA)

5	Immune Checkpoint InhibitorsIBA 02/2024 - 01/2022
5	Biomarkers (Surrogate Marker)IBA 02/2023 - 12/2007
5	Immunoglobulin G (IgG)IBA 01/2021 - 04/2011
4	AntibodiesIBA 01/2016 - 04/2011
3	IpilimumabIBA 09/2022 - 01/2013
3	Proteins (Proteins, Gene)FDA Link 09/2022 - 04/2011
3	Monoclonal AntibodiesIBA 01/2018 - 04/2011
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2018 - 04/2013
3	AnthracyclinesIBA 07/2014 - 12/2006
2	CytokinesIBA 09/2022 - 04/2011
2	Trastuzumab (Herceptin)FDA Link 01/2019 - 08/2005
2	Bevacizumab (Avastin)FDA Link 01/2018 - 05/2014
2	InterferonsIBA 05/2017 - 04/2011
2	Taxoids (Taxanes)IBA 02/2014 - 09/2002
2	Gemcitabine FDA Link 02/2014 - 03/2003
2	Estrogen ReceptorsIBA 09/2012 - 08/2010
2	Albumin-Bound Paclitaxel FDA Link 01/2006 - 11/2005
1	Blood Proteins (Serum Proteins)IBA 02/2023
1	Polysaccharides (Glycans)IBA 02/2023
1	PRIMMIBA 01/2023
1	NivolumabIBA 09/2022
1	Interleukin-6 (Interleukin 6)IBA 09/2022
1	pembrolizumabIBA 09/2022
1	Cell-Free Nucleic AcidsIBA 01/2022
1	N 30IBA 01/2022
1	VaccinesIBA 01/2021
1	BNT162 VaccineIBA 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Sodium Fluoride (Ossin)FDA Link 04/2019
1	FluoridesIBA 04/2019
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 04/2019
1	Trinitrotoluene (TNT)IBA 01/2018
1	PlatinumIBA 01/2018
1	Carboplatin (JM8)FDA LinkGeneric 01/2018
1	Messenger RNA (mRNA)IBA 01/2018
1	AntigensIBA 01/2016
1	Immunoglobulins (Immunoglobulin)IBA 11/2015
1	AlbuminsIBA 10/2015
1	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 10/2015
1	taxaneIBA 07/2014
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2014
1	Paclitaxel (Taxol)FDA LinkGeneric 02/2014
1	Epirubicin (Ellence)FDA LinkGeneric 02/2014
1	Neoplasm Antigens (Tumor Antigens)IBA 04/2013
1	Interleukin-10 (Interleukin 10)IBA 04/2013
1	Interleukin-4 (Interleukin 4)IBA 04/2013
1	VemurafenibIBA 01/2013
1	dabrafenibIBA 01/2013
1	Tamoxifen FDA LinkGeneric 09/2012
1	Transaminases (Aminotransferases)IBA 04/2011
1	Fibronectins (Fibronectin)IBA 04/2011
1	Interleukin-12 (IL 12)IBA 04/2011
1	Docetaxel (Taxotere)FDA Link 12/2006
1	Methylprednisolone FDA LinkGeneric 03/2003
1	Cisplatin (Platino)FDA LinkGeneric 03/2003
1	Platinum Compounds (Compounds, Platinum)IBA 09/2002
1	Cytotoxins (Cytolysins)IBA 09/2002

Therapy/Procedure

10	Therapeutics 11/2023 - 12/2007
7	Drug Therapy (Chemotherapy) 01/2019 - 09/2002
3	Neoadjuvant Therapy 07/2014 - 08/2010
1	Mediterranean Diet 01/2023
1	Radiotherapy 01/2022
1	Emergency Treatment 12/2017
1	Injections 10/2016
1	Immunotherapy 01/2016
1	Salvage Therapy 03/2003